6.8M XNAS Volume
XNAS 11 Apr, 2025 5:30 PM (EDT)
GET EVENTS ALERTS
LIVE SAMPLE
Board Meetings - ImmunityBio Inc
The next board meeting for ImmunityBio Inc is on 09 May 2025 for the purpose of ImmunityBio Inc First Quarter Earnings Results for 2025
Share
| Ex-date | Purpose | Notes |
|---|---|---|
| 12 Aug 2025 | ImmunityBio Inc Second Quarter Earnings Results for 2025 | - |
| 11 Jun 2025 | ImmunityBio Inc Annual General Meeting for 2025 | - |
| 09 May 2025 | ImmunityBio Inc First Quarter Earnings Results for 2025 | - |
| 19 Mar 2025 | ImmunityBio Inc Annual Report for 2024 | - |
| 03 Mar 2025 | ImmunityBio Inc Annual Report for 2024 | - |
| 03 Mar 2025 | ImmunityBio Inc Fourth Quarter Earnings Results for 2024 | - |
| 19 Nov 2024 | ImmunityBio to Participate in the Jefferies London Healthcare Conference | - |
| 15 Nov 2024 | ImmunityBio Inc Third Quarter Earnings Results for 2024 | - |
| 12 Nov 2024 | ImmunityBio Inc Third Quarter Earnings Results for 2024 | - |
| 08 Nov 2024 | ImmunityBio Inc Third Quarter Earnings Results for 2024 | - |
| 15 Aug 2024 | ImmunityBio Inc Second Quarter Earnings Results for 2024 | - |
| 12 Aug 2024 | ImmunityBio Inc Second Quarter Earnings Results for 2024 | - |
| 08 Aug 2024 | ImmunityBio Inc Second Quarter Earnings Results for 2024 | - |
| 13 Jun 2024 | ImmunityBio Inc Annual General Meeting for 2024 | - |
| 11 Jun 2024 | ImmunityBio Inc Annual General Meeting for 2024 | - |
| 10 May 2024 | ImmunityBio Inc First Quarter Earnings Results for 2024 | - |
| 09 May 2024 | ImmunityBio Inc First Quarter Earnings Results for 2024 | - |
| 05 May 2024 | AUA 2024 (QUILT 2.005: A comparison of intravesical Bacillus Calmette-Guerin (BCG) in combination with the IL-15 superagonist N-803 to BCG alone in patients with BCG-naïve NMIBC) | - |
| 03 May 2024 | AUA 2024 (MP16-03: N-803 plus BCG Complete Response rate in NMIBC CIS) | - |
| 26 Apr 2024 | ImmunityBio Inc FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer 2024 | - |
| 24 Apr 2024 | ImmunityBio announces positive overall survival results of anktiva combined with checkpoint inhibitors in non-small cell lung cancer; meeting scheduled with fda to discuss registration path for anktiva in lung cancer | - |
| 19 Mar 2024 | ImmunityBio Inc Annual Report for 2023 | - |
| 01 Mar 2024 | ImmunityBio Inc Annual Report for 2023 | - |
| 09 Nov 2023 | ImmunityBio Inc Third Quarter Earnings Results for 2023 | - |
| 08 Aug 2023 | ImmunityBio Inc Second Quarter Earnings Results for 2023 | - |
| 13 Jun 2023 | ImmunityBio Inc Annual General Meeting for 2023 | - |
| 11 May 2023 | ImmunityBio Inc First Quarter Earnings Results for 2023 | - |
| 01 Mar 2023 | ImmunityBio Inc Annual Report for 2022 | - |
| 09 Nov 2022 | ImmunityBio Inc Third Quarter Earnings Results for 2022 | - |
| 08 Aug 2022 | ImmunityBio Inc Second Quarter Earnings Results for 2022 | - |
| 14 Jun 2022 | ImmunityBio Inc Annual General Meeting for 2022 | - |
| 10 May 2022 | ImmunityBio Inc First Quarter Earnings Results for 2022 | - |
| 01 Mar 2022 | ImmunityBio Inc Annual Report for 2021 | - |
| 12 Nov 2021 | ImmunityBio Inc Third Quarter Earnings Results for 2021 | - |
| 12 Aug 2021 | ImmunityBio Inc Second Quarter Earnings Results for 2021 | - |
| 10 Jun 2021 | ImmunityBio Inc Annual General Meeting for 2021 | - |
| 14 May 2021 | ImmunityBio Inc First Quarter Earnings Results for 2021 | - |